Speedy recovery: Low-Dose sedative gets breast cancer patients home in under 2 hours
NCT ID NCT07180810
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested whether a low dose of the sedative dexmedetomidine could help women leave the hospital sooner after day-case breast cancer surgery. 82 women were randomly assigned to receive either the drug or a placebo during surgery. The main goal was to see how many could be discharged within 2 hours. The results could point to a simple way to speed up recovery and improve comfort after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dexmedetomidine
- What this could lead to
- If it works, this could help women recover faster and go home sooner after breast cancer surgery, reducing hospital stays.
- What could go wrong
- This is a small, completed trial with 82 participants. The drug may cause side effects like low heart rate or drowsiness, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
82 people
The number who actually took part.
- Started
-
Sep 2023
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-60 yrs, ASA 1 and 2, elective breast cancer surgery Exclusion Criteria: * BMI greater than 35, CKD stage 3 or greater, known drug allergy to study drug, bradycardia, history of PONV, patients on antiepileptics
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shaukat Khanum Memorial Cancer Hospital and Research Centre
Lahore, Pubjab, 54782, Pakistan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a faster radiation course match the standard one after breast reconstruction?
- Can High-Risk breast cancer patients skip an extra radiation boost?
- Radioactive probe lights up CD73 on breast tumors in PET scans
- Can time with horses help cancer patients feel better?
- Can an oral drug replace injections for advanced breast cancer?
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?